multiple myeloma is a plasma cell neoplasm that is currently incurable. older patients are managed with melphalan and prednisolone. Younger patients have induction chemotherapy followed by high-dose melphalan and autologous stem cell transplantation. Recent insights into the biological basis of myeloma have resulted in several new drugs becoming available. Thalidomide, bortezomib and lenalidomide have each improved the response to therapy, but they are expensive. Future challenges include optimising the sequence of these drugs, refining their combination with standard drugs and highdose therapy, and identifying the subgroups of patients most likely to benefit from them.
Introduction
Multiple myeloma is a malignant proliferation of plasma cells that characteristically secrete a monoclonal protein. This is measured in the laboratory as paraprotein or free light chains in blood, or Bence-Jones protein in urine. 1 Clinically the disease is associated with a combination of hypercalcaemia, renal failure, anaemia and lytic bone lesions. While multiple myeloma remains incurable in the majority of cases, the considerable developments in our therapeutic armamentarium over recent years have significantly improved survival.
Treatment overview
Oral melphalan and prednisolone have been the backbone of myeloma therapy for many years. This combination, with or without newer drugs, remains the standard of care for older patients. Younger patients who are eligible for transplantation have induction chemotherapy followed by high-dose melphalan with autologous stem cell rescue. This approach has led to an improvement in median overall survival from 42 to 54 months. 2 While there are a number of induction regimens, the combination of vincristine, doxorubicin and dexamethasone has been most frequently used. An oral induction regimen containing cyclophosphamide, idarubicin and dexamethasone is increasingly being used.
Currently, the treatment approach for newly diagnosed myeloma is guided by the patient's eligibility for autologous haematopoietic stem cell transplantation (Fig. 1 ). Most Australian centres will consider transplantation in patients aged up to 65 years depending on their general health. Autologous stem cell transplantation for myeloma has a treatment-related mortality of 1-2%.
Supportive care
Both before and during treatment attention must be given to 
New drugs
In recent years, evidence supporting a survival benefit for thalidomide, bortezomib and lenalidomide has resulted in their w w w. a u s t ra l i a n p re s c riber.com
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A suggested approach to treatment of patients with newly diagnosed multiple myeloma In the younger patient group, thalidomide combined with dexamethasone is an effective pre-transplantation induction regimen. 3 It has also been used as 'maintenance' following high-dose therapy and autologous stem cell transplantation. 3 Maintenance therapy with thalidomide increased four-year overall survival from 77% to 87% in studies of patients after autologous stem cell transplantation. 3 The Therapeutic Goods Administration (TGA) has approved thalidomide in firstline treatment and for relapsed or refractory myeloma, but Pharmaceutical Benefits Scheme (PBS) funding is currently only available for relapsed or refractory myeloma.
Adverse effects
The most frequent adverse effects seen with thalidomide are constipation, fatigue, somnolence and peripheral neuropathy.
As thalidomide significantly increases the risk of venous thrombosis, prophylaxis should be considered (aspirin, warfarin or low molecular weight heparin is recommended).
Thalidomide use is strictly regulated due to its teratogenicity. In Australia, patients, prescribers and dispensing pharmacists must be registered with the Pharmion Risk Management Program.
They have to complete phone questionnaires emphasising the importance of effective contraception before receiving authority for each 28-day prescription. Distribution of the drug is carefully controlled and tracked.
Lenalidomide
Lenalidomide is an oral thalidomide analogue and acts by similar mechanisms, targeting both signalling pathways within the malignant plasma cell and the bone marrow microenvironment. After promising initial results as a single drug, trials comparing lenalidomide plus dexamethasone with dexamethasone alone found superior response rates (60% vs 24%) and improved median overall survival in relapsed myeloma. 5 Trials involving newly diagnosed patients have shown an 81% response rate when combined with melphalan and prednisolone in elderly patients, and a 91% response rate when combined with dexamethasone in younger transplanteligible patients. 6, 7 Lenalidomide is frequently effective even in patients whose myeloma is resistant to thalidomide.
Although approved by the TGA for relapsed disease, lenalidomide is not presently subsidised by the PBS.
Haematologists can currently access lenalidomide through a temporary expanded access program established by the drug company.
Adverse effects
Unlike thalidomide, lenalidomide is not associated with somnolence, constipation or peripheral neuropathy, but causes neutropenia and thrombocytopenia. Thromboembolic events occur at an increased rate, hence antithrombotic prophylaxis is recommended. Effective contraception is also required given its teratogenic potential.
Bortezomib
Just as the use of thalidomide arose from an understanding of the importance of angiogenesis in myeloma, the development of bortezomib followed new insights into the importance of the proteasome. This is the intracellular structure responsible for orderly degradation of intracellular proteins. Proteasomal inhibition by bortezomib results in cellular apoptosis, particularly in malignant and proliferating cells.
Early studies showed that intravenous bortezomib had a higher response rate and a six-month survival advantage over highdose dexamethasone in relapsed myeloma. The median overall survival was 29.8 months with bortezomib versus 23.7 months with dexamethasone. 8 In newly diagnosed elderly patients, bortezomib used with melphalan and prednisolone resulted in a response rate of 89%, with overall survival being 90% at 16 months versus 62% in those treated with melphalan and prednisolone alone. 9 Younger transplant-eligible patients had similarly impressive response rates when bortezomib was included in induction regimens. 10 In Australia, bortezomib is currently subsidised by the PBS for 
Adverse effects
The major adverse effects of bortezomib include fatigue, gastrointestinal upset, painful peripheral neuropathy, anaemia, thrombocytopenia and neutropenia. There is also an increased incidence of herpes simplex and herpes zoster infections.
Related conditions
Monoclonal gammopathy of undetermined significance is an asymptomatic clonal plasma cell proliferation, but 1% of patients progress to myeloma every year. These patients require careful monitoring, but treatment is not indicated. While myeloma remains incurable, these new therapies are substantially changing our approach to this disease.
More importantly, they have the potential to further improve survival as we continue to determine their optimal place in the management of this common haematological malignancy.
